key: cord-0426426-k5wkqwg9
authors: Boswell, Kristin L.; Watkins, Timothy; Cale, Evan M.; Samsel, Jakob; Andrews, Sarah F.; Ambrozak, David R.; Driscoll, Jefferson I.; Messina, Michael A.; Narpala, Sandeep; Hopp, Christine S.; Cagigi, Alberto; Casazza, Joseph P.; Yamamoto, Takuya; Zhou, Tongqing; Schief, William R.; Crompton, Peter D.; Ledgerwood, Julie E.; Connors, Mark; Gama, Lucio; Kwong, Peter D.; McDermott, Adrian; Mascola, John R.; Koup, Richard A.
title: Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings
date: 2022-03-30
journal: bioRxiv
DOI: 10.1101/2022.03.29.485179
sha: 8e5a7878316c0de7096a1656f3c94bd88691ca33
doc_id: 426426
cord_uid: k5wkqwg9

The isolation and characterization of neutralizing antibodies from infection and vaccine settings will inform future vaccine design, and methodologies that streamline the isolation of antibodies and the generation of B cell clones are of great interest. Retroviral transduction to express Bcl-6 and Bcl-xL in primary B cells has been shown to promote long-term B cell survival and antibody secretion in vitro, and can be used to isolate antibodies from memory B cells. The application of this methodology to B cell subsets from tissues and to B cells from individuals with chronic infection has not been extensively characterized. Here, we characterize Bcl-6/Bcl-xL B cell immortalization across multiple tissue types and B cell subsets in healthy and HIV-1 infected individuals, as well as individuals recovering from malaria. In HIV-1- and malaria-uninfected donors, naïve and memory B cell subsets from PBMC and tonsil tissue transformed with similar efficiencies, and displayed similar characteristics after transformation with respect to their longevity and immunoglobulin secretion. In HIV-1-viremic individuals or in individuals after malaria infection, the CD27-CD21- memory B cell subsets transformed with lower efficiencies compared to the CD27+CD21+ populations, but following transformation B cells expanded and secreted IgG with similar efficiency. Using B cells from HIV-1-infected individuals, we combined Bcl-6/Bcl-xL B cell immortalization with a HIV-1 microneutralization assay to isolate broadly neutralizing antibodies related to VRC13 and VRC38.01. Overall, Bcl-6/Bcl-xL B cell immortalization can be used to isolate antibodies and generate B cell clones from multiple different B cell populations, albeit with different efficiencies.

The isolation and characterization of neutralizing antibodies from infection and vaccine 24 settings will inform future vaccine design, and methodologies that streamline the isolation of (1-4). Thus, efficient strategies to isolate antibodies from memory B cells following infection or 52

vaccination are needed to not only inform future vaccine design, but also to identify novel 53

Multiple strategies exist to isolate antigen-specific B cells (5). One strategy includes 55 using a recombinant fluorophore-labeled antigen probe to isolate antigen-specific B cells by The efficiency and application of Bcl-6 and Bcl-xL expression in specific B cell subsets has 77 not been fully explored, and in select conditions this technology may be limited. For example, 78 in cases where biopsy samples or fine needle aspirates of draining lymph nodes are available, 79

antigen-specific B cell responses from B cell follicles and germinal centers can be studied. 80

Germinal center B cells isolated from secondary lymphoid organs (SLO), however, more readily 81 undergo cell death during in vitro culture and antibody discovery techniques that rely on long-82 term B cell culture may be limited (12). In chronic infection settings such as HIV-1, malaria or 83 tuberculosis, memory B cell populations characterized by the low expression of CD27 and CD21, 84 sometimes referred to as "atypical", "tissue-like" or "exhausted", can expand to comprise up to 85 40-50% of the memory B cell pool in PBMC (13-17). In general, CD27 -CD21 -B cell populations 86 are characterized by the high expression of inhibitory receptors and have an impaired ability to 87

To better understand the application of Bcl-6 and Bcl-xL B cell transformation to 140 different B cell subsets, we compared the efficiency of Bcl-6/Bcl-xL transformation of naïve and 141 memory B cells isolated from human PBMC, and naïve and memory subsets isolated from 142 human tonsil. For PBMC, we sorted IgD + (naïve) and IgD -IgM -IgG + (IgG + memory) B cells and 143 activated them in the presence of recombinant human IL-21 (25 ng/ml) and irradiated 3T3- and IgD -CD20 + CD38 -IgG + (non-germinal center (Non-GC) IgG + ) B cells and transduced the 151 populations as described above ( Figure 1B ). Similar to B cell populations isolated from PBMC of 152 healthy subjects, we again observed transduction efficiencies between 45-80% for all B cell 153 subsets based on GFP expression ( Figure 1D, F) . 154

In addition to determining the frequency of GFP + B cells, we calculated the expansion of 155 B cell subsets from the initial activation through 4 days post-transduction (6 days total). 156

Overall, while we did observe differences between subjects, we found that the total number of 157 CD19 + B cells expanded between 4-fold to 40-fold, with IgG + B cells from the tonsil expanding 158 less compared to naïve B cells ( Figure 1E ,F). Thus, while there are differences between B cell 159 subsets regarding their ability to proliferate in response to CD40L and IL-21 ex vivo, the overall 160 transduction efficiency of 45-80% is measured within a population of B cells that have 161 expanded. Following transduction and expression of Bcl-6 and Bcl-xL, all GFP + B cells continue 162 to expand and to express surface immunoglobulin (Supplemental Figure 2A-C) . 163

To evaluate the efficiency of transformed naïve and IgG + memory B cell subsets to 165 expand in microculture, and to determine the amount of immunoglobulin secreted, we 166 compared microcultures of transformed B cells isolated from naïve and memory B cells from 167 both PBMC and tonsil tissue. Transduced B cells were sorted into 384-well microculture plates 168 at 1, 2 or 5 GFP + cells per well at four days post-transduction. Cultures were supplemented 169 with fresh media, IL-21 and irradiated CD40L-feeder cells every four days. On day 24 of culture, 170

we measured IgM and IgG concentrations in the culture supernatant of transformed naïve and 171 memory B cells, respectively. When sorted at 1 cell per well, between 20 and 33% of the 172 memory wells had detectable levels of IgG, while between 32 and 38% of the naive wells had 173 detectable levels IgM (Figure 2A ). Within the positive wells, the median immunoglobulin 174 concentration ranged from 0.39 µg/mL to 1.5 µg/mL for IgG with greater median 175 concentrations for IgM at 7.3 to 8.3 µg/mL for PBMC and tonsil cells, respectively. Sorting 2 and 176 5 GFP + B cells per well resulted in an increased frequency of positive wells at day 24 with a 177 slight, but not significant increase in the median immunoglobulin concentration (Figure 2A) . Generation of antigen-specific naïve and IgG + memory B cell clones 203

We next asked whether we could generate antigen-specific memory B cell clones from 204 both naïve and memory B cell subsets. To generate naïve B cell clones, we isolated CD27 -IgD + B 205 cells from PBMC of a healthy donor and transduced the cells with the Bcl-6/Bcl-xL retroviral 206 vector. Following transduction, we stained the cells with eOD-GT8, a probe that binds to 207 VRC01-class B cells that target the CD4 binding site (27), and the eOD-GT8 knockout probe 208 (eOD-GT8 KO), which has been mutated within the CD4 binding site and is used to avoid sorting 209 off-target B cells (28) ( Figure 3A ). From the GFP + eOD-GT8 KOpopulation we sorted the eOD-210 GT8 + B cells into a microculture plate at 1 cell per well. After allowing the B cells to expand, we 211 sequenced the clonal B cells to determine their BCR sequence. Based on the sequence data we 212 determined that clone IMMO-A1, which is of the VH1-2 family and contains a 5 amino acid long 213 L-CDR3, is a VRC01 precursor B cell line ( Figure 3B ). Clone C1, which contains a VH1-2 sequence 214 without a 5 amino acid long L-CDR3, and clone A2, which is not a member of the VH1-2 family, 215 are also shown. After expansion and freeze/thaw, clone IMMO-A1 maintains its ability to bind 216 to eOD-GT8. 217

We also applied B cell immortalization to isolate memory B cell clones in the context of 218 influenza vaccination, where H7N9-naïve individuals were immunized with H7N9 and subjects 219 demonstrated B cell responses to not only the the H7 hemagglutinin (HA), but also had cross-220 reactive memory B cell responses to other HA molecules, such as the H3 HA. (29-31). In this 221 context, B cell clones can be used to help characterize not only HA binding but also to 222 demonstrate BCR activation in response to different HA molecules. To generate H7 HA-specific 223 B cell clones we sorted IgG + B cells from PBMC and following transduction we stained the 224 transduced cells with H7 HA and H3 HA fluorophore-conjugated probes, and subsequently 225 sorted all H7 HA-positive B cells at 1 cell per well for microculture ( Figure 3C ). After clonal 226 expansion we sequenced and characterized clones for binding to H7 and H3 HA, of which Clone 227 1 and Clone 2 are shown ( Figure 3D ). We found the HA clones maintained their specificity from 228 the single cell sort through clonal expansion, with Clone 1 binding to both H7 and H3 HA, and 229

Clone 2 binding to the H7 HA but not to the H3 HA ( Figure 3D ). In addition, we found the clones 230 maintained their specificity with respect to B cell activation as detected by the phosphorylation 231 ERK as measured by flow cytometry, similar to what has been described for tetanus-specific B 232 cells (9). The anti-IgG F(ab')2 and H7 HA promoted phosphorylation of ERK in both clones, 233

whereas the H3 HA induced phosphorylation of ERK in only Clone 1 ( Figure 3D ). Thus, 234

immortalized clones can be used to demonstrate that immunogens not only bind to a specific 235 BCR but also to activate signalling through the BCR. there are some differences in the VH gene usage amongst the H7 HA-specific clones, there is 243 not a major skewing of the repertoire when comparing the ex vivo probe-sorted repertoire to 244 that of the immortalized probe-sorted repertoire. 245

In chronic infection settings, the CD27 -CD21 -B cell population, which has a markedly 247 reduced ability to proliferate in vitro, increases in frequency within PBMC. Since antigen-248 specific antibodies can be found within this population, we characterized the efficiency of 249 immortalization within this population. We sorted the CD27 -CD21and CD27 + CD21 + 250 populations from 3 healthy individuals, 3 HIV-1-viremic individuals (viral loads: 385, 4503 and 251 608,544 copies/mL) and 4 individuals recovering from febrile malaria at one week after 252 treatment (convalescence). Within the HIV-1-infected and malaria convalescent donors, we 253 observed that the ex vivo CD27 + CD21 + population was decreased compared to healthy donors 254 and that the CD27 -CD21population was increased compared to healthy subjects ( Figure 4A , 255 4B). We observed significant differences in the transduction efficiencies between the 256 CD27 + CD21 + and CD27 -CD21population across all donors (p<0.0001) and differences across 257 multiple subsets based on CD27 and CD21 expression ( Figure On day 7 we analyzed the surface phenotype of the transduced (GFP + ) and non-transduced 262 (GFP -) populations and found that the GFP + cells continued to express CD20 and surface IgG, 263

with GFPcells losing expression of these markers (Supplemental Figure 5C ). Interestingly, we 264 found that the GFP + cells expressed CD21 but little to no CD27 irrespective of the starting 265 population. To evaluate the efficiency of B cell expansion and secretion in microculture, we 266 sorted 2 GFP + B cells per well into a 384-well plate and cultured the cells for 24 days. Although 267 not statistically significant, we found the CD27 -CD21population tended to result in fewer IgG + 268 positive wells compared to the CD27 + CD21 + population, but that IgG + wells contained similar 269 median concentrations of IgG ( Figure Figure 6C , D). These data demonstrate that HIV-1-specific antibodies can be 282 isolated from the CD27 -CD21population by B cell immortalizaton. 283

To determine if B cell immortalization can be used to isolate bNAbs from HIV-1-infected 285 individuals, we applied the technology to donors from which bNAbs have previously been 286 isolated. Antibody VRC38.01 was previously isolated from donor N90 while VRC13 was isolated indicates the antibody isolated from donor N90 (well 5J18) is a relative of VRC38, while the 294 antibody isolated from Pt.44 (well 3E06) is related to VRC13 ( Figure 5C ). Of note, the 295 immortalization procedure was repeated for Pt.44 and a second VRC13 relative was isolated 296

(well E3). The antibody isolated from Donor N90 (well 5J18) utilizes the same V and J genes as 297 VRC38.01 for both the heavy and light chains and share the same CDRH3 and CDRL3 sequences. 298

Similarly, the two antibodies isolated from Pt.44 share the same V and J genes for both the 299 heavy and light chains as VRC13, and within the CDR3 regions residues that differ from VRC13 300 are highlighted in red ( Figure 5C ). 301

Single point neutralization assays were performed against a 31-virus panel for the three 302 cloned antibodies and between 29 and 32% of viruses were neutralized by more that 50% 303 ( Figure 5D ). The cloned antibodies, along with VRC13 and VRC38.01 were further tested for 304 neutralization against a panel of 17 viruses that showed sensitivity in the single-point assay. 305

The antibody isolated from well 5J18 showed similar potency and breadth as compared to 306 VRC38.01, whereas the two antibodies isolated from Pt.44 display less potency and breadth as 307 compared to VRC13 ( Figure 5E ). Overall, these studies serve as a proof-of-principle that B cell 308 immortalization can be used to isolate bNAbs. Because we did detect differences between B cell subsets during activation and 360 following transduction, and because individual clones do expand at different rates, the utility of 361 this methodology as a means to characterize the B cell repertoire is unclear. Using influenza 362 vaccination as a model system, we compared the H7 HA-immortalized B cell repertoire to that 363 of a previously characterized repertoire using the same samples and the same probes as bait as 364 previously published (30). In general, both methodologies detected large clonal expansions but 365 there was less overlap with rarer clones, with some clones detected with only ex vivo sorting, 366 and others detected after immortalization and clonal expansion. And while some of these 367 discrepancies can be attributed to the depth of sequencing, they may also be attributed to the 368 variable efficiency of B cell immortalization in different B cell subsets. In general however, we 369 did not detect a major bias in the immortalized H7 HA-specific B cell repertoire compared to the 370 previously published ex vivo repertoire (30). Therefore, while B cell immortalization can be 371 used to isolate rare antibodies and generate B cell clones, its application to accurately study the 372 B cell repertoire needs to be further explored. 373

As B cell clones are expanded for increased screening and analysis, one potential 374 concern is whether the clones acquire mutations during the in vitro culture, and whether the 375 final sequence of the desired clone represents the sequence of the primary B cell. In our 376 experimental setting, while we did detect mutations during the microculture, we found these 377 mutations to be minimal. Some of the mutations may be due to PCR error, although some 378 certainly represent actual mutations as we observed more mutations on day 24 of culture 379 compared to day 8 using the same sequencing protocol. Overall, we found that by sequencing In addition, immortalized B cell clones can serve as tools to characterize the capacity of 393 novel immunogens to not only bind to antigen-specific B cells but also to induce B cell signaling. 394

In combination with a high-throughput B cell activation assay, such as detection of containing polybrene (4 µg/mL). Briefly, 1 mL I10 media was removed from the well of the 12-497 well plate and replaced with 1 mL fresh viral supernatant (48-hour retroviral supernatant) 498 containing polybrene. The plate was centrifuged at 1200xg for 1 hour at 32 o C, rested for 1 hour 499 at 37 o C and 5% CO2 before the viral supernatant was replaced with fresh I10 containing 25 500 ng/mL IL-21 and cultured at 37 o C and 5% CO2 overnight. The same procedure was repeated the 501 following day using the 72-hour retroviral supernatant. B cells were then rested for ~3 days 502 before determining transduction efficiency by flow cytometry and sorting for microculture. 503

Transformed B cells cultured in bulk were maintained in 12-well plates. Cells were split 1:4 505 every 3-4 days into wells containing 2 x10 5 3T3-msCD40L cells and 25 ng/mL human IL-21 in 506 1mL of I10. Cell counts were measured by flow cytometry using counting beads (BD 507

Biosciences) and data were collected on a modified LSRII or a modified FACSymphony. For 508 microculture, transformed B cells were sorted 3 days following transduction. Briefly, 509 transformed B cells were sorted at 1-5 B cells/well into a 384-well plate containing 5 x 10 3 510 irradiated 3T3-msCD40L, human IL-21 (25 ng/mL) in 50 µL of I10. Every 4 days cells were fed by 511

replacing 25 µl of media with fresh I10 containing irradiated 2.5 x 10 3 3T3-msCD40L cells and 50 512 ng/mL IL-21 using a Biomek NX P liquid handler (Beckman Coulter). Cells were cultured for 2-3 513 weeks before harvesting the final supernatant and either freezing the cultures in the 384-well 514 plate (50ul freezing media per well (FBS + 10% DMSO)), or expanding selected wells to 96-well 515 tissue culture plates. 516

Concentrations of total IgG and IgM in the culture supernatant were determined by ELISA 518 (ThermoFisher) according to the manufacturer's instruction. 519

Immunoglobulin amplification and sequencing 520 B cells were dry-sorted into a 96-well PCR plate at 1-2 cells per well and multiplex polymerase 521 chain reaction (PCR) was used to amplify the heavy and/or light chain sequences as previously 522 described (7). PCR products were sequenced by ACGT, Inc., Eurofins or Genewiz and analyzed 523 using Geneious Prime and the IMGT database (42, 43) . 524

To characterize the accumulation of mutations during in vitro culture, IgG + B cells from PBMC of 526 in stain buffer and incubated with anti-ERK1/2 (pT202/pY204 Alexa647) (BD Biosciences) for 30 546 minutes at room temperature. Cells were subsequently washed and data were collected on a 547 modified LSRII (BD Immunocytometry Systems) and analyzed using Flowjo (TreeStar). 548

Standard MSD 384 well streptavidin coated SECTOR®Imager 2400 plates were blocked with 35 550 µL of 5% (W/V) MSD Blocker A and incubated for 1 hour at room temperature (RT) on a 551

Heidolph Titramax 100 vibrational plate shaker at 650 rpm. All incubations in this assay were 552 performed as described above. The plates were washed three times with 0.05%Tween PBS 553 (wash buffer) and were coated with biotinylated BG505 SOSIP DS-FPV1 10ln QQ AVI protein 554 (Biotin Trimer 7070 capture) at an optimized concentration of 1 μg/mL for 1 hour. 1% MSD 555

Blocker A was used as the diluent in the assay. The test samples (B cell supernatants) were 556 diluted 1 to 1 with assay diluent in dilution plates. After 1 hour of incubation, the plates were 557 washed again with the wash buffer and the serial diluted test samples were added to MSD 558 plates. After an hour of incubation with the samples, the plates were washed again, and SULFO-559 TAG conjugated goat anti-human secondary detection antibody was used for detection at an 560 optimized concentration of 1 μg/mL. After an additional hour of incubation, the unbound 561 secondary detection antibody was washed off the plates and the plates were read using 1X 562 MSD Read Buffer on the MSD Sector Imager 2400. 563

Antibody purification from B cell culture supernatants 564 B cells from the CD27 + CD21 + and CD27 -CD21populations that displayed greater relative 565 neutralization against pseudoviruses expressing HIV-1 envelopes BG505.T32N and MW965.26 566 in the TZM-bl microneutralization assay were expanded in serum free media hybridoma media 567 (Gibco) that was supplemented with irradiated feeder cells and IL-21. Supernatants were 568 concentrated and IgG was purified using Ab Spintrap columns (GE Healthcare/Cytiva). 569

Screening small volumes of B cell culture supernatants for HIV-1 neutralizing activity was 571 performed using the HIV-1 microneutralization assay as described (44) 

The Antibody Society: Therapeutic monoclonal antibodies approved or in review in the 600 EU or US

Broadly neutralizing antibodies for HIV-1 prevention and therapy

Broadly Neutralizing Antibodies for HIV Eradication. Curr 604 HIV/AIDS Rep

Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A 607 Review

Tools to therapeutically harness the human antibody response

A method for 611 identification of HIV gp140 binding memory B cells in human blood

Efficient 614 generation of monoclonal antibodies from single human B cells by single cell RT-PCR and 615 expression vector cloning

Isolation of human 617 monoclonal antibodies from peripheral blood B cells

619 Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B 620 cells by genetic programming

Genetic 622 manipulation of B cells for the isolation of rare therapeutic antibodies from the human 623 repertoire

Stable long-term cultures of self-625 renewing B cells and their applications

Germinal center 627 cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis

Evidence for HIV-630 associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected 631 viremic individuals

Atypical memory B cells 633 are greatly expanded in individuals living in a malaria-endemic area

B-cell exhaustion in HIV infection: the role of immune activation

Atypical memory B cells in 638 human chronic infectious diseases: An interim report

Exhaustion may not be in the human B cell 640 vocabulary, at least not in malaria

Malaria-associated atypical 642 memory B cells exhibit markedly reduced B cell receptor signaling and effector function

Abnormal B cell 645 memory subsets dominate HIV-specific responses in infected individuals

Atypical and 648 classical memory B cells produce Plasmodium falciparum neutralizing antibodies

HIV-1 neutralizing antibodies: understanding nature's pathways

Determinants of 653 HIV-1 broadly neutralizing antibody induction

Correlates of broadly neutralizing antibody development

Germline-targeting immunogens

Targeting broadly neutralizing antibody precursors: a naive approach to 659 vaccine design

Rational HIV 661 immunogen design to target specific germline B cell receptors

HIV-1 broadly 663 neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Priming HIV-1 broadly 666 neutralizing antibody precursors in human Ig loci transgenic mice

An avian 669 influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical 670 trial

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells 673 after H7N9 immunization in humans

Activation 675 Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory 676 B cell Responses to Influenza Hemagglutinin

Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple 679 Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

Virus-like Particles 682 Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop

Structural Repertoire 685 of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

Genetic modification 688 of primary human B cells to model high-grade lymphoma

Structural Basis for Broad 690 HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell 691 Host Microbe

Plasmodium falciparum-693 specific IgM B cells dominate in children, expand with malaria, and produce functional IgM

An intensive longitudinal 696 cohort study of Malian children and adults reveals no evidence of acquired immunity to 697 Plasmodium falciparum infection

Comparative oncogenomics 699 identifies NEDD9 as a melanoma metastasis gene

Flow cytometry 701 reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig 702 heavy-chain lineages

Rational design of 704 envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

IMGT/V-QUEST: the highly customized and 707 integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids 708 Res

Geneious 710 Basic: an integrated and extendable desktop software platform for the organization and 711 analysis of sequence data

Measuring HIV neutralization in a luciferase reporter gene assay